Avidity shares are trading higher after the company announced initial AOC 1020 data from the Phase 1/2 FORTITUDE trial demonstrating reductions of greater than 50% in DUX4 regulated genes, trends of functional improvement, and favorable safety and tolerability in people living with facioscapulohumeral muscular dystrophy.
Portfolio Pulse from Benzinga Newsdesk
Avidity shares are trading higher following the announcement of positive initial data from the Phase 1/2 FORTITUDE trial for AOC 1020, showing significant reductions in DUX4 regulated genes and trends of functional improvement in patients with facioscapulohumeral muscular dystrophy.
June 12, 2024 | 12:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Avidity shares are trading higher after the company announced positive initial data from the Phase 1/2 FORTITUDE trial for AOC 1020, showing significant reductions in DUX4 regulated genes and trends of functional improvement in patients with facioscapulohumeral muscular dystrophy.
The positive initial data from the Phase 1/2 FORTITUDE trial for AOC 1020 is a significant milestone for Avidity, demonstrating both efficacy and safety. This news is likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100